Effects of angiotensin II and losartan in the forearm of patients with essential hypertension. 1998

J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
Department of Nephrology, Leiden University Medical Centre, The Netherlands. J.Baan@AMC.UVA.NL

OBJECTIVE Angiotensin II type 1 receptor-mediated constrictor effects may be modulated by hypertension-related vascular changes, changes in receptor function and in neurohumoral activity. METHODS The forearm blood flow (FBF) effects of angiotensin II, methoxamine, and losartan were investigated in essential hypertensive patients. Minimal forearm vascular resistance was measured to determine structural vascular changes. METHODS Seven hypertensive patients were selected, and seven matched normotensives. Angiotensin II (0.01-10 ng/kg per min) was infused during predilatation by sodium nitroprusside (6.1 +/- 0.6 ng/kg per min) before and during losartan infusion (0.3-3 microg/kg per min). Methoxamine (0.2-2 microg/kg per min) was co-infused with the nitric oxide synthase inhibitor NG-monomethyl-L-arginine. FBF, measured by venous occlusion plethysmography, was expressed as the change in FBF ratio (FBFinfused arm/FBFnon-infused arm). RESULTS Baseline FBF (infused arm) was increased by sodium nitroprusside from 2.56 +/- 0.80 to 5.46 +/- 0.92 (P<0.05) and from 2.66 +/- 0.25 to 5.42 +/- 0.40 ml/100 ml per min (P<0.05) in the hypertensive and normotensive group, respectively. Baseline forearm vascular resistance (FVR) was higher in the hypertensive than in the normotensive group [51 +/- 8 versus 33 +/- 3 mmHg/ (ml/100 ml per min); P<0.05]. Angiotensin II caused a maximal change in FBF ratio (Emax) by -70 +/- 3 and -72 +/- 6% in the hypertensive and normotensive group, respectively (NS). Tachyphylaxis did not occur. Infusions of losartan at 0.3, 1 and 3 microg/kg per min reduced the Emax values from -70 +/- 3 to -50 +/- 5, -45 +/- 5 and -15 +/- 2%, respectively, in the hypertensive group, and from -72 +/- 6 to -62 +/- 4, -45 +/- 2 and -32 +/- 2%, respectively, in the normotensive group (NS). Infusion of methoxamine significantly reduced the FBF ratio by -58 +/- 6 and -69 +/- 5% in the hypertensive and normotensive groups, respectively (NS). Minimal FVR, after forearm ischemia, was the same in hypertensives and normotensives, namely 3.2 +/- 0.7 and 3.2 +/- 0.4 mmHg/(ml per 100 ml per min), respectively (NS). CONCLUSIONS Angiotensin II type 1- and alpha1-mediated vascular effects were unchanged by essential hypertension. Baseline FVR was greater in the hypertensives than in the normotensives, while minimal FVR was the same. These results indicate that the forearm vascular bed of the patient group studied does not show important structural and renin-angiotensin system-related functional changes as a result of hypertension.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008729 Methoxamine An alpha-1 adrenergic agonist that causes prolonged peripheral VASOCONSTRICTION. Methoxamedrin,Methoxamine Hydrochloride,Metoxamine Wellcome,Vasoxin,Vasoxine,Vasoxyl,Vasylox,Hydrochloride, Methoxamine,Wellcome, Metoxamine
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D005542 Forearm Part of the upper extremity in humans and primates extending from the ELBOW to the WRIST. Antebrachium,Antebrachiums,Forearms
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
December 1994, American journal of hypertension,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
November 1995, Journal of hypertension,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
January 1999, Blood pressure,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
May 1996, Journal of clinical pharmacology,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
April 1995, Journal of human hypertension,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
August 1976, Australian and New Zealand journal of medicine,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
August 1976, Australian and New Zealand journal of medicine,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
July 2001, Hypertension (Dallas, Tex. : 1979),
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
January 1993, American journal of hypertension,
J Baan, and P C Chang, and P Vermeij, and M Pfaffendorf, and P A van Zwieten
April 1999, American journal of hypertension,
Copied contents to your clipboard!